PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34970856-2	2022	The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID-19.	Colchicine	21-31	NLR family pyrin domain containing 3	Homo sapiens	4-9	
18973929-3	2009	RESULTS: Assessment, after review of 1512 publications, is that oral colchicine therapy is being refined by attention to novel targets such as NALP3 and pyrin.	Colchicine	69-79	NLR family pyrin domain containing 3	Homo sapiens	143-148	
34970856-9	2022	DISCUSSION AND CONCLUSION: The ability of colchicine to reduce the length of stay in hospitalized patients with COVID-19 is consistent with its potential to prevent clinical deterioration via inhibition of NLRP3 inflammasome.	Colchicine	42-52	NLR family pyrin domain containing 3	Homo sapiens	206-211	
34492522-0	2021	Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	41-46	
34906598-7	2021	Furthermore, the non-selective NLRP3 inhibitor colchicine has been recently shown to significantly reduce cardiovascular events in patients with chronic coronary disease.	Colchicine	47-57	NLR family pyrin domain containing 3	Homo sapiens	31-36	
34650351-3	2021	COLCOT (in patients with recent MI) and LoDoCo2 (in patients with chronic coronary syndromes) tested oral colchicine (an NLRP3 inflammasome inhibitor) 0.5 mg daily vs. placebo, demonstrating prevention of MACE with a slightly increased risk of pneumonia in COLCOT (0.9 vs. 0.4%) but not in LoDoCo2.	Colchicine	106-116	NLR family pyrin domain containing 3	Homo sapiens	121-126	
34599390-7	2021	Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	28-33	
34492522-2	2021	Colchicine has broad anti-inflammatory effects and part of the atheroprotective effects have been suggested to be the result of NLRP3 inflammasome inhibition.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	128-133	
34492522-10	2021	EV NLRP3 protein levels were lower in patients treated with colchicine (median 1.38 ng/mL), compared to placebo (median 1.58 ng/mL) (p = 0.025).	Colchicine	60-70	NLR family pyrin domain containing 3	Homo sapiens	3-8	
34492522-14	2021	CONCLUSIONS: Colchicine leads to a reduction of EV NLRP3 protein levels.	Colchicine	13-23	NLR family pyrin domain containing 3	Homo sapiens	51-56	
34492522-15	2021	This indicates that inhibitory effects on the NLRP3 inflammasome might contribute to the atheroprotective effects of colchicine in coronary disease.	Colchicine	117-127	NLR family pyrin domain containing 3	Homo sapiens	46-51	
35046517-9	2022	At the molecular level, colchicine reduces proinflammatory cytokine release and inhibits NF-kappaB signaling and NLRP3 inflammasome activation.	Colchicine	24-34	NLR family pyrin domain containing 3	Homo sapiens	113-118	
34312998-4	2021	In atherosclerosis, colchicine can inhibit the assembly and activation of NLRP3 inflammasome via various mechanisms to effectively reduce the expression of inflammatory factors, thereby reducing the inflammation.	Colchicine	20-30	NLR family pyrin domain containing 3	Homo sapiens	74-79	
35178861-0	2022	Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	80-85	
35178861-3	2022	The anti-inflammatory drug colchicine exerts its effects, in part, via reducing NLRP3 activity, and has been shown to improve several cardiac diseases, including acute coronary syndrome and pericarditis.	Colchicine	27-37	NLR family pyrin domain containing 3	Homo sapiens	80-85	
35178861-11	2022	Evaluation of components of the NLRP3 inflammasome revealed an increased percentage of apoptosis-associated speck-like protein containing a CARD domain (ASC)-expressing, caspase-1-expressing, and interleukin-1beta-expressing cells in the myocardium and in the spleen of CVB3 + PBS vs. control mice, which was reduced in CVB3 + colchicine compared with CVB3 + PBS mice.	Colchicine	327-337	NLR family pyrin domain containing 3	Homo sapiens	32-37	
35178861-15	2022	In both CVB3 FB and HL-1 cells, colchicine down-regulated the NLRP3 inflammasome-related components ASC, caspase-1, and IL-1beta.	Colchicine	32-42	NLR family pyrin domain containing 3	Homo sapiens	62-67	
35178861-16	2022	CONCLUSIONS: Colchicine improves LV function in CVB3-induced myocarditis, involving a decrease in cardiac and splenic NLRP3 inflammasome activity, without exacerbation of CVB3 load.	Colchicine	13-23	NLR family pyrin domain containing 3	Homo sapiens	118-123	
35113170-0	2022	Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	35-40	
35113170-3	2022	Since colchicine is an anti-inflammatory drug with the ability to block NLRP3 inflammasome oligomerization, this may prevent the release of active IL-1beta and block the detrimental effects of downstream cytokines, i.e. IL-6.	Colchicine	6-16	NLR family pyrin domain containing 3	Homo sapiens	72-77	
35113170-5	2022	As colchicine is a nonspecific inhibitor of the NLRP3 inflammasome, compounds specifically blocking this molecule might provide increased advantages in reducing the inflammatory burden and its related clinical manifestations.	Colchicine	3-13	NLR family pyrin domain containing 3	Homo sapiens	48-53	
33337127-6	2021	This pathway is confirmed indirectly by the beneficial effect of colchicine (an indirect NLRP3 inflammasome inhibitor) and IL-1 blockers in patients with recurrent pericarditis.	Colchicine	65-75	NLR family pyrin domain containing 3	Homo sapiens	89-94	
33968934-2	2021	The anti-inflammatory action of colchicine seems to result from irreversible inhibition of tubulin polymerization and microtubule (MT) assembly by binding to the tubulin heterodimer, avoiding the signal transduction required to the activation of the entire NLRP3 inflammasome.	Colchicine	32-42	NLR family pyrin domain containing 3	Homo sapiens	257-262	
32611559-3	2020	Colchicine has a unique anti-inflammatory mechanism: it is not only able to concentrate in leucocytes, especially neutrophils, and block tubulin polymerisation, affecting the microtubules assembly, but also inhibits (NOD)-like receptor protein 3 (NLRP3) inflammasome.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	247-252	
33110739-7	2020	Anecdotal experiences have been reported with the use of the anti-IL-1 agent anakinra and the NLRP3 inflammasome inhibitor colchicine in this population.	Colchicine	123-133	NLR family pyrin domain containing 3	Homo sapiens	94-99	
29352570-4	2018	In this review, we describe the role of monocytes/macrophages and neutrophils in atherosclerosis, outline mechanisms of activation of the NLRP3 inflammasome in the setting of atherosclerosis-associated inflammation and discuss potential therapies that specifically target the NLRP3 inflammasome and/or its downstream mediators in atherosclerosis, with a particular focus on the emerging role of colchicine.	Colchicine	395-405	NLR family pyrin domain containing 3	Homo sapiens	138-143	
30591286-11	2019	Recent demonstration that cholesterol crystals trigger the NLRP3 (nucleotide oligomerization domain-, leucine-rich repeat-, and pyrin domain-containing protein 3) inflammasome and the release of inflammatory cytokines that also drive uric acid crystal-induced inflammation indicates that the multiple actions of colchicine that make it effective in gout may be relevant to preventing inflammation and limiting inflammatory injury in atherosclerosis.	Colchicine	312-322	NLR family pyrin domain containing 3	Homo sapiens	59-64	
32808940-4	2020	Studies show that colchicine, among other actions, inhibits the assembly of NLRP3 complex that is responsible for generating the active form of Caspase-1 that will convert Pro-IL-1beta and Pro-IL-18 into their active forms.	Colchicine	18-28	NLR family pyrin domain containing 3	Homo sapiens	76-81	
32733639-9	2020	Therefore, we conclude that colchicine plays a crucial role in alleviating the intracellular inflammatory response and NLRP3 inflammation activation, attenuating the levels of cellular oxidative stress and pyroptosis in endothelial cells via regulating AMPK/SIRT1 signaling, which may be a concrete mechanism for the secondary prevention of cardiovascular diseases.	Colchicine	28-38	NLR family pyrin domain containing 3	Homo sapiens	119-124	
31522718-0	2019	Colchicine inhibits endothelial inflammation via NLRP3/CRP pathway.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	49-54	
31558729-5	2019	Anti-inflammatory agents, such corticosteroids, NSAIDs and colchicine, are widely used for the treatment of gout flare; recognition of the importance of NLRP3 inflammasome activation and bioactive IL-1beta release in initiation of the gout flare has led to the development of anti-IL-1beta biological therapy for gout flares.	Colchicine	59-69	NLR family pyrin domain containing 3	Homo sapiens	153-158	
29904810-2	2018	RECENT FINDINGS: Recent evidence about therapeutic targets on pericarditis has demonstrated that NALP3 inflammasome blockade is the cornerstone in the clinical benefits of colchicine.	Colchicine	172-182	NLR family pyrin domain containing 3	Homo sapiens	97-102	
27129183-0	2016	Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	85-90	
29232311-9	2018	Concurrent treatment with lithium and low-dose colchicine could facilitate the responsiveness of bipolar patients to lithium by reducing leukocyte tissue emigration, the release of neutrophil elastase, and the release of leukocyte pro-inflammatory cytokines such as IL-1beta that are regulated by the NLRP3 inflammasome assembly complex.	Colchicine	47-57	NLR family pyrin domain containing 3	Homo sapiens	301-306	
22870500-6	2012	The potential of colchicine as a prophylactic agent in managing recurrent attacks and the likely mechanisms of its effects on the NACHT, LRR and PYD domains-containing protein 3 (NALP-3) inflammasome of the innate immune system are highlighted.	Colchicine	17-27	NLR family pyrin domain containing 3	Homo sapiens	130-177	
26304941-2	2015	Colchicine is believed to block the NLRP3 inflammasome, a cytosolic complex responsible for the production of IL-1beta and IL-18.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	36-41	
27241260-0	2016	Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	23-28	
27241260-7	2016	Colchicine, a medication classically used for gout, mediates its anti-inflammatory effect by inhibiting tubulin polymerization, and has been shown to attenuate macrophage NLRP3 inflammasome arrangement and activation in vitro and in vivo.	Colchicine	0-10	NLR family pyrin domain containing 3	Homo sapiens	171-176	
25864748-4	2015	This study was undertaken to analyze whether disrupting the microtubule cytoskeleton by colchicine modulates transcriptional levels of MEFV, NF-kappaB p65, NLRP3, HMGB1, and caspase-3 in neutrophils from patients with familial Mediterranean fever (FMF) and healthy subjects.	Colchicine	88-98	NLR family pyrin domain containing 3	Homo sapiens	156-161	
25864748-5	2015	In the present study, colchicine caused increased expression of NLRP3 (p=0.007) and MEFV (p=0.03), but had no effect on caspase-3, NF-kappaB p65 and HMGB1 genes in healthy neutrophils.	Colchicine	22-32	NLR family pyrin domain containing 3	Homo sapiens	64-69	
22870500-6	2012	The potential of colchicine as a prophylactic agent in managing recurrent attacks and the likely mechanisms of its effects on the NACHT, LRR and PYD domains-containing protein 3 (NALP-3) inflammasome of the innate immune system are highlighted.	Colchicine	17-27	NLR family pyrin domain containing 3	Homo sapiens	179-185